Australia markets closed

(GENE)

. Currency in USD
Add to watchlist
- (-)
Full screen
Trade prices are not sourced from all markets
Previous close2.7100
Open2.8000
BidN/A x N/A
AskN/A x N/A
Day's range2.7300 - 2.8400
52-week range1.8000 - 6.0000
Volume35,850
Avg. volumeN/A
Market cap10.811M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.1500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GTG Global Collaborations and Innovation Update

    MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groupsContinuous development of the geneType portfolioA deep pipeline of new unique and ground-breaking tests Strong Global Academi

  • GlobeNewswire

    GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

    MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200

  • Simply Wall St.

    One Genetic Technologies Insider Raised Stake By 20% In Previous Year

    Looking at Genetic Technologies Limited's ( ASX:GTG ) insider transactions over the last year, we can see that insiders...